Resveratrol - A prostate cancer chemopreventive agent?

Urologic Oncology

Volumn 7, Issue 6, 2002, Pages 223-227

  Ratan, Hari L ^a   Steward, Will P ^a   Gescher, Andreas J ^a   Mellon, J Kilian ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Chemoprevention; Prostatic neoplasms; Resveratrol

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN RECEPTOR; ANTIOXIDANT; CYTOCHROME P450; EPIGALLOCATECHIN GALLATE; FINASTERIDE; FLAVONOID; GENISTEIN; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHENOL; POLYPHENOL DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; QUERCETIN; RESVERATROL; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; STILBENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CELL CYCLE; CELL SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG SCREENING; ENZYME REGULATION; GRAPE; HUMAN; METASTASIS; NONHUMAN; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; WESTERN EUROPE; CANCER INCIDENCE; DRUG EFFICACY; DRUG SYNTHESIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CHEMOPREVENTION; HUMANS; NEOPLASMS; RECEPTORS, ANDROGEN; STILBENES;

EID: 0036868156     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(02)00194-1     Document Type: Review

References (38)

1. Greenlee R., Murray T., Bolden S. Cancer statistics 2000. CA Cancer J Clin. 50:2000;7-33.
2. Kelloff G., Lieberman R., Steele V.et al. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology. 57(Suppl 4A):2001;46-51.
3. Fisher B., Constantino J., Wickerham D.et al. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst. 90:1998;1371-1388.
4. Whittemore A., Wu A., Kolonel L. Family history and prostate cancer risk in black, white and Asian men in the United States and Canada. Am J Epidemiol. 141:1995;732-740.
5. Zaridze D., Boyle P., Smans M. International trends in prostate cancer. Int J Cancer. 33:1984;223-230.
6. Denis L., Morton M., Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol. 35:1999;377-387.
7. Sakir W., Partin A. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology. 57(Suppl 4A):2001;115-120.
8. Bostwick D. Prostatic intraepithelial neoplasia. current concepts J Cell Biochem. 16:1992;10-19.
9. Thompson I., Kouril M., Klein E.et al. The Prostate Cancer Prevention trial. current status and lessons learned Urology. 57(Suppl 4A):2001;230-234.
10. Klein E., Thompson I., Lippman S.et al. Select. The next prostate cancer prevention trial J Urol. 166:2001;1311-1315.
11. Giovannucci E., Clinton S. Tomatoes, lycopene and prostate cancer. Proc Soc Exp Biol Med. 218:1998;129-139.
12. Bergan R., Waggle D., Carter S.et al. Tyrosine kinase inhibitors and signal transduction modulators. rationale and current status as chemopreventive agents for prostate cancer Urology. 57(Suppl 4A):2001;77-80.
13. Gusman J., Malonne H., Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis. 22:2001;1111-1117.
14. Jang M., Cai L., Udeani G.et al. Cancer chemopreventative activity of Resveratrol, a natural product derived from grapes. Science. 275:1997;218-220.
15. Hsieh T., Wu J. Differential effects on growth, cell cycle arrest and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res. 249:1999;109-115.
16. Mitchell S., Zhu W., Young C. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 59:1999;5892-5895.
17. Sharma P., Schreiber-Agus N. Mouse models of prostate cancer. Oncogene. 18:1999;5349-5355.
18. Mentor-Marcell R., Lamartiniere I., Eltomn E., Greenberg N., Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 61:2001;6777-6782.
19. Gupta S., Hastak K., Ahmad N., Lewin J., Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA. 98:2001;10350-10355.
20. DeWeese T., Hruszkewycz A., Marnett L. Oxidative stress in chemprevention trials. Urology. 57:2001;137-140.
21. Ripple M., Henry W., Rago R., Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostae carcinoma cells. J Natl Cancer Inst. 89:1997;40-48.
22. Martinez J., Moreno J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol. 59:2000;865-870.
23. Kampa M., Hatzoglou A., Notas G.et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer. 37:2000;223-233.
24. Jang M., Pezzuto J. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res. 25:1999;65-77.
25. Holmes-McNary M., Baldwin A. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IKB kinase. Cancer Res. 60:2001;3477-3483.
26. Gupta S., Srivastava M., Ahmad N. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 42:2000;73-78.
27. Chaudry A., Wahle K., McClinton S. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro. effects of fatty acids and cyclooxygenase inhibitors Int J Cancer. 57:1994;176-180.
28. Sawaoka H., Tsuji S., Tsuji M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumour growth in vivo. Lab Invest. 79:1999;1469-1477.
29. Subbaramaiah K., Chung W.J., Michaluart P.et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbal-ester treated human mammary epithelial cells. J Biol Chem. 273:1998;21875-21882.
30. Ciolino H., Yeh G. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol. 56:1999;760-767.
31. Williams J., Martin F., Muir G.et al. Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis. 21:2000;1683-1689.
32. Huang C., Wei-ya M., Goranson A., Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis. 20:1999;237-242.
33. Ahmad N., Adhami V., Afaq F., Feyes D., Mukhtar H. Resveratrol causes WAF-1/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res. 7:2001;1466-1473.
34. Fontecave M., Lepoivre M., Elleingand E., Gerez C., Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421:1998;277-279.
35. Sun N., Woo S., Cassady J., Snapka R. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod. 61:1998;362-366.
36. Visakorpi T., Hyytinen E., Koivisto P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature. 9:1995;401-406.
37. Hsieh T., Wu J. Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen-receptor (AR) - independent mechanism. Anticancer Res. 20:2000;225-228.
38. Lu S., Liu M., Epner D., Tsai S., Tsai M. Androgen regulation of the cyclin dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol. 13:1999;376-384.